Allergan receives FDA approval for Ozurdex for use in certain DME patients

Article

Allergan recently announced it has received U.S. Food and Drug Administration (FDA) approval for Ozurdex (dexamethasone intravitreal implant) 0.7 mg as a new treatment option for diabetic macular edema (DME) in adult patients who have an artificial lens implant (pseudophakic) or are scheduled for cataract surgery (phakic).

Irvine, CA-Allergan recently announced it has received U.S. Food and Drug Administration (FDA) approval for Ozurdex (dexamethasone intravitreal implant) 0.7 mg as a new treatment option for diabetic macular edema (DME) in adult patients who have an artificial lens implant (pseudophakic) or are scheduled for cataract surgery (phakic). 

Ozurdex is a sustained-release, biodegradable steroid implant that demonstrated long-term efficacy without the need for monthly injections. The implant uses the Novadur solid polymer delivery system, a biodegradable implant that releases medicine over an extended period of time to suppress inflammation.

Ozurdex is already indicated for the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion and for the treatment of non-infectious uveitis affecting the posterior segment of the eye.

The latest FDA approval for Ozurdex is based on the Macular Edema: Assessment of Implantable Dexamethasone in Diabebetes (MEAD) study, which includes two multi-center, three-year, sham-controlled, masked, randomized clinical studies assessing the proportion of patients with 15 or more letters improvement in best-corrected visual acuity from baseline. The most common adverse events during the MEAD studies included cataracts and elevated intraocular pressure (IOP). An increase in mean IOP was seen with each treatment cycle, but the mean IOP generally returned to baseline between treatment cycles. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Shelby Brogdon, OD, details opportunities for practices to answer the patient's concerns from the chair before they hit the internet for their contact lens needs.
Christi Closson, OD, FAAO, shares her excitement for the new Acuvue Oasys MAX 1-Day multifocal for astigmatism
Karen R. Hoffman, OD, shares how customizable scleral lenses can transform vision for patients with complex corneas, achieving 20/20 outcomes and enhanced comfort.
Janna Pham, OD, shares key takeaways from a corneal tomography session she presented alongside Travis Pfeifer, OD, and Matthew McGee, OD.
Jacob Lang, OD, FAAO, details early symptom relief demonstrated in as early as day 1 during AOA's Optometry's Meeting 2025.
When Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, began fitting scleral lenses 20 years ago, there was limited knowledge about conjunctival characteristics, scleral shape, and lens behavior.
Ioussifova details what sets Johnson & Johnson's new lens apart from the rest, which was launched at the American Optometric Association's Optometry's Meeting 2025.
Alongside Rachel Steele, OD, Rafieetary outlines what to look for in blurred disc margins and the importance of acting fast and sending patients to the ED when needed.
Langis Michaud, OD, MSc, FAAO, FSLS, FBCLA, FEAOO, emphasized that every staff member should play a role in myopia management during his presentation at Optometry's Meeting 2025.
Dr Ashley Tucker Wallace discusses the intersection of pediatric dry eye and myopia control
© 2025 MJH Life Sciences

All rights reserved.